INTRODUCTION
1
PART I
4
Item 1.
Identity of Directors, Senior Management and Advisers
Item 2.
Offer Statistics and Expected Timetable
Item 3.
Key Information
A. Selected Financial Data
B. Capitalization and Indebtedness
6
C. Reasons for the Offer and Use of Proceeds
D. Risk Factors
Item 4.
Information on the Company
24
A. Business Overview
27
B. Government Regulations
53
C. Property, Plants and Equipment
54
Item 4A.
Unresolved Staff Comments
55
Item 5
Operating and Financial Review and Prospects
A. Research and Development, Patents and Licenses
78
B. Trend Information
C. Off-Balance Sheet Arrangements
D. Tabular Disclosure of Contractual Obligations
79
Item 6.
Directors, Senior Management and Employees
80
A. Directors and Senior Management
B. Board Practices
88
C. Employees
103
D. Share Ownership
104
Item 7.
Major Shareholders and Related Party Transactions
106
A. Major Shareholders
B. Related Party Transactions
108
C. Interests of Experts and Counsel
Item 8.
Financial Information
A. Consolidated Statements and Other Financial Information
B. Significant Changes
109
Item 9.
The Offer and Listing
A. Offer and Listing Details
B. Plan of Distribution
C. Markets
D. Selling Shareholders
E. Dilution
F. Expense of the Issue
110
Item 10.
Additional Information
A. Share Capital
B. Memorandum and Articles of Association
C. Exchange Controls
111
D. Taxation
112
E. Dividends and Paying Agents
129
F. Statement by Experts
G. Documents on Display
H. Subsidiary Information
130
Item 11.
Quantitative and Qualitative Disclosures about Market Risk
Item 12.
Description of Securities Other than Equity Securities
PART II
Item 13.
Defaults, Dividend Arrearages and Delinquencies
Item 14.
Material Modifications to the Rights of Security Holders
Item 15.
Controls and Procedures
Item 16.
[Reserved]
Item 16A.
Audit Committee Financial Expert
Item 16B.
Code of Ethics
Item 16C.
Principal Accountants Fees and Services
Item 16D.
Exemptions from the Listing Standards for Audit Committee
Item 16E.
Purchase of Equity Securities By Issuer and Affiliated Purchases
Item 16F.
Change in Registrant’s Certifying Accountant.
Item 16G.
Corporate Governance.
PART III
Item 17.
Financial Statements
Item 18.
Item 19.
Exhibits
Also, Piedmont is a provider of services on Safran and Liebherr Landing Gear systems, to do so, Piedmont is dependent on these OEM’s to provide parts and engineering support.
TAT’s future success depends on its ability to develop new offerings and technologies.
The markets we serve are characterized by rapid changes in technologies and evolving industry standards. In addition, some of our products are installed on, and some of our services are provided in connection with, platforms that may have a limited life or become obsolete. Unless we develop new offerings or enhance our existing offerings we may be susceptible to loss of market share resulting from the introduction of new or enhanced offerings by competitors. For example, revenues of the overhaul and coating of jet engine components segment from MRO services for the Pratt & Whitney JT8D jet engine comprise a material portion of such segment’s total revenues. In recent years, the JT8D jet engine is being replaced with new engines in newer types of aircrafts that have been manufactured in recent years. If we will not develop MRO offerings for newer types of jet engines, it will have a material adverse impact on the business and results of operations of the overhaul and coating of jet engine components segment. In fiscal year 2019, the revenues of the overhaul and coating of jet engine components segment accounted for approximately 8.4% of TAT’s total revenues.
We are vulnerable to the global economic effects of epidemics and other public health crises, such as the novel strain of COVID-19 virus. Due to the recent outbreak of the COVID-19 virus, there has been a substantial curtailment of global travel and business activities which could have an impact on airline spending and demand, and could negatively impact our sales if conditions worsen or extend for a prolonged period of time. Supply chain and manufacturing disruptions could negatively impact our sales. If not resolved quickly, the impact of the epidemic could have a material adverse effect on our business.